Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement
- 10 July 2020
- journal article
- research article
- Published by Elsevier BV in Psychiatry Research
- Vol. 291, 113285
- https://doi.org/10.1016/j.psychres.2020.113285
Abstract
No abstract availableThis publication has 89 references indexed in Scilit:
- Galantamine potentiates the neuroprotective effect of memantine against NMDA‐induced excitotoxicityBrain and Behavior, 2013
- Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantaminePsychopharmacology, 2011
- Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitationsBiochemical Pharmacology, 2011
- Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistryNeuroscience, 2010
- Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutonsProceedings of the National Academy of Sciences of the United States of America, 2010
- The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?Schizophrenia Bulletin, 2010
- Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in SchizophreniaSchizophrenia Bulletin, 2010
- High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophreniaSchizophrenia Research, 2008
- BDNF up-regulates α7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneuronsMolecular and Cellular Neuroscience, 2006
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986